We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.90 | 2.53% | 36.50 | 35.70 | 36.00 | 35.60 | 35.50 | 35.60 | 247,788 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.35 | 107.05M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/7/2023 09:41 | LiarBOoth even has the gall to quote this: 'diversity of opinion on bulletin boards is not welcome.' Especially by him! | petroc | |
07/7/2023 09:40 | For a small company with only 12 employees including directors, pharmaceutical company Futura Medical (FUM:AIM) punches way above its weight. It has created the first significant innovation in the erectile dysfunction market in over 20 years with its proprietary transdermal DermaSys technology. Having secured UK and European regulatory approval for its fast-acting erectile dysfunction gel the company received the green light on 12 June from the US Food and Drug Administration to sell into the world’ Approval means the gel, called Eroxon, is the only erectile dysfunction product permitted in the US without a prescription. The shares have gained around 36% since the approval and have doubled over the last year to 58p, giving the company a market value of £167 million. Futura is having discussions with potential US partners to get the product into market. Ultimately the company wants to establish a global network of licensing and distribution partners to build brand awareness, healthcare credibility and marketing expertise. The global erectile dysfunction market generated sales of $3 billion in 2020 with one in five men suffering from it, including around 22 million in the US and 20 million across the UK, Germany, France, Italy and Spain. Eroxon was launched across Europe in March and the UK in April 2023 and is available through Boots stores as well as Amazon. The brand partner is Cooper Consumer Health. Existing treatments such as Pfizer’ It can take 30 to 60 minutes for these pills to have an effect which reduces the spontaneity element. Secondly, there are side-effects ranging from headaches to hot flushes which deter long-term use. Futura says Eroxon works within 10 minutes of application and because the product is effectively a device and not an oral pill, there is less risk of it affecting other parts of the body, unlike rival treatments. hxxps://www.sharesma | petroc | |
06/7/2023 17:22 | There goes LiarBOoth spamming the board again, trying to drown out all the opposing opinions! He's changed since he posted this: LiarBOoth, 25th Sept 2017: '... neither of you are helping yourselves by carrying on in the current manner and taking over the bulletin board.' The hypocrisy and irony is overwhelming from the lying stock basher. | petroc | |
06/7/2023 16:23 | LiarBOoth even has the gall to quote this: 'diversity of opinion on bulletin boards is not welcome.' Especially by him! For a small company with only 12 employees including directors, pharmaceutical company Futura Medical (FUM:AIM) punches way above its weight. It has created the first significant innovation in the erectile dysfunction market in over 20 years with its proprietary transdermal DermaSys technology. Having secured UK and European regulatory approval for its fast-acting erectile dysfunction gel the company received the green light on 12 June from the US Food and Drug Administration to sell into the world’ Approval means the gel, called Eroxon, is the only erectile dysfunction product permitted in the US without a prescription. The shares have gained around 36% since the approval and have doubled over the last year to 58p, giving the company a market value of £167 million. Futura is having discussions with potential US partners to get the product into market. Ultimately the company wants to establish a global network of licensing and distribution partners to build brand awareness, healthcare credibility and marketing expertise. The global erectile dysfunction market generated sales of $3 billion in 2020 with one in five men suffering from it, including around 22 million in the US and 20 million across the UK, Germany, France, Italy and Spain. Eroxon was launched across Europe in March and the UK in April 2023 and is available through Boots stores as well as Amazon. The brand partner is Cooper Consumer Health. Existing treatments such as Pfizer’ It can take 30 to 60 minutes for these pills to have an effect which reduces the spontaneity element. Secondly, there are side-effects ranging from headaches to hot flushes which deter long-term use. Futura says Eroxon works within 10 minutes of application and because the product is effectively a device and not an oral pill, there is less risk of it affecting other parts of the body, unlike rival treatments. hxxps://www.sharesma | petroc | |
06/7/2023 14:02 | What's up, LiarBOoth? Your last two copy/pasted spamming posts haven't been ticked up yet. I wonder why! | petroc | |
06/7/2023 11:25 | From what I've seen and read about FUM they are proficient at putting in Patent Protection requests as they've have several patents already. Also it can take up to 18 months for a patent to be approve, from what I've read before. but I could be wrong. | keifer derrin | |
06/7/2023 10:33 | I wrote to FUM to ask about patent extension application and got this back:« Many thanks for your enquiry. By way of introduction, Optimum is a specialist healthcare IR and PR firm which is working with Futura Medical to support its ongoing investor relations. In Q2 2022, as part of its overall IP protection strategy, Futura filed national patent applications considered necessary to protect the commercial interests of MED3000 in line with normal PCT filing procedures in all key ED markets. If successful, this will provide patent protection until 2040. Please see link to PR here. »2 questions:Is it normal to have to wait so long for a patent extension approval ie since Q2 2022?I see that FUM only have 15 employees. How on earth do they do all the research and testing necessary to create a proprietary product? Do they out source this etc? | beanol | |
06/7/2023 10:31 | LiarBOoth even has the gall to quote this: 'diversity of opinion on bulletin boards is not welcome.' Especially by him! For a small company with only 12 employees including directors, pharmaceutical company Futura Medical (FUM:AIM) punches way above its weight. It has created the first significant innovation in the erectile dysfunction market in over 20 years with its proprietary transdermal DermaSys technology. Having secured UK and European regulatory approval for its fast-acting erectile dysfunction gel the company received the green light on 12 June from the US Food and Drug Administration to sell into the world’s largest market of erectile dysfunction sufferers. Approval means the gel, called Eroxon, is the only erectile dysfunction product permitted in the US without a prescription. The shares have gained around 36% since the approval and have doubled over the last year to 58p, giving the company a market value of £167 million. Futura is having discussions with potential US partners to get the product into market. Ultimately the company wants to establish a global network of licensing and distribution partners to build brand awareness, healthcare credibility and marketing expertise. The global erectile dysfunction market generated sales of $3 billion in 2020 with one in five men suffering from it, including around 22 million in the US and 20 million across the UK, Germany, France, Italy and Spain. Eroxon was launched across Europe in March and the UK in April 2023 and is available through Boots stores as well as Amazon. The brand partner is Cooper Consumer Health. Existing treatments such as Pfizer’s (PFE:NYSE) Viagra and Eli Lilly’s (LLY:NYSE) Cialis have drawbacks. Both products no longer have patent protection and they are facing cheaper generic competition. It can take 30 to 60 minutes for these pills to have an effect which reduces the spontaneity element. Secondly, there are side-effects ranging from headaches to hot flushes which deter long-term use. Futura says Eroxon works within 10 minutes of application and because the product is effectively a device and not an oral pill, there is less risk of it affecting other parts of the body, unlike rival treatments. hxxps://www.sharesma | petroc | |
06/7/2023 10:03 | For a small company with only 12 employees including directors, pharmaceutical company Futura Medical (FUM:AIM) punches way above its weight. It has created the first significant innovation in the erectile dysfunction market in over 20 years with its proprietary transdermal DermaSys technology. Having secured UK and European regulatory approval for its fast-acting erectile dysfunction gel the company received the green light on 12 June from the US Food and Drug Administration to sell into the world’s largest market of erectile dysfunction sufferers. Approval means the gel, called Eroxon, is the only erectile dysfunction product permitted in the US without a prescription. The shares have gained around 36% since the approval and have doubled over the last year to 58p, giving the company a market value of £167 million. Futura is having discussions with potential US partners to get the product into market. Ultimately the company wants to establish a global network of licensing and distribution partners to build brand awareness, healthcare credibility and marketing expertise. The global erectile dysfunction market generated sales of $3 billion in 2020 with one in five men suffering from it, including around 22 million in the US and 20 million across the UK, Germany, France, Italy and Spain. Eroxon was launched across Europe in March and the UK in April 2023 and is available through Boots stores as well as Amazon. The brand partner is Cooper Consumer Health. Existing treatments such as Pfizer’s (PFE:NYSE) Viagra and Eli Lilly’s (LLY:NYSE) Cialis have drawbacks. Both products no longer have patent protection and they are facing cheaper generic competition. It can take 30 to 60 minutes for these pills to have an effect which reduces the spontaneity element. Secondly, there are side-effects ranging from headaches to hot flushes which deter long-term use. Futura says Eroxon works within 10 minutes of application and because the product is effectively a device and not an oral pill, there is less risk of it affecting other parts of the body, unlike rival treatments. hxxps://www.sharesma | petroc |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions